Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer

Is there a potential benefit associated with the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in female breast cancer survival and cancer recurrence among patients with obesity or with type 2 diabetes (T2D)?In this cohort study using propensity score–matched data from 841 831 patients with breast cancer, GLP-1 RA use vs nonuse was significantly associated with improved survival and reduced recurrence among patients with obesity. Similar benefits were seen among patients with T2D when compared with other antidiabetic medications.This study suggests that GLP-1 RAs may offer protective benefits beyond glycemic and weight control, potentially improving survival and recurrence risk in some female patients with breast cancer.

Corresponding Author: Bernard F. Fuemmeler, PhD, MPH, Massey Comprehensive Cancer Center, 830 E Main St, Box 980212, Richmond, VA 23286 (bernard.fuemmeler@vcuhealth.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.